Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

Load latest

Wockhardt Ltd.

07 Feb 2025

1294.00

-1.23%

Company Update

WOCKHARDT LTD. - 532300 - Statement On Deviation Or Variation Of Funds Raised Through Qualified Institutions …

BSE India

Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we hereby confirm that there has been no deviation in the utilisation of the issue proceeds from the object as stated in the Placement Documents dated 26th March 2024 and 11th November 2024 and accordingly, the Statements of Deviations in the prescribed format confirming Nil deviation duly reviewed by the Audit Committee are attached

pdf

Wockhardt Ltd.

07 Feb 2025

1294.00

-1.23%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

BSE India

Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173(A) of the SEBI ( Issue of Capital and Disclosure Requirements) Regulations, 2018, please find attached Monitoring Agency Reports towards utilisation of proceeds of following Qualified institutions Placements ("QIPs") for the quarter ended 31st December, 2024 issued by CRISIL Rating Limited, duly reviewed and taken on record by Board of Directors & Audit Committee of the Company 1. QIP of Rs. 480.04 crore vide Placement Document dated 26.03.2024 (Annexure 1) 2. QIP of Approx. Rs. 1000 crore vide Placement Document dated 11.11.2024 (Annexure 2)

pdf

Wockhardt Ltd.

07 Feb 2025

1294.00

-1.23%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results(Standalone and Consolidated) for the quarter and nine months ended 31st December, 2024

pdf

Wockhardt Ltd.

07 Feb 2025

1294.00

-1.23%

Wockhardt Q3 Results: Pharma Major Swings Back To Profit As Expenses Fall

NDTV Profit

On the operating side, Ebitda jumped 84.6% to Rs 96 crore, while margin expanded to 13.3% from 7.4%.

Wockhardt Ltd. is trading above its 200 day SMA of 1219.7

Wockhardt Ltd.

07 Feb 2025

1294.00

-1.23%

Board Meeting

WOCKHARDT LTD. - 532300 - Board Meeting Outcome for Outcome Of The Board Meeting

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'); and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2024-25/086 dated 3rd February, 2025, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 7th February, 2025, inter-alia, have approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2024

pdf

Wockhardt Ltd.

03 Feb 2025

1294.00

-1.23%

Board Meeting

WOCKHARDT LTD. - 532300 - Board Meeting Intimation for Intimation Of The Meeting Of Board Of …

BSE India

WOCKHARDT LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and is closure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Friday, 7th February, 2025, inter-alia, to consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2024

pdf

Wockhardt Ltd.

31 Jan 2025

1294.00

-1.23%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Wockhardt''s Zaynich (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary infection (cUTI) achieving 96.8% clinical cure rate"

pdf

Wockhardt Ltd.

14 Jan 2025

1294.00

-1.23%

Company Update

WOCKHARDT LTD. - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Compliance Certificate received from MUFG Intime India Pvt Ltd (Formerly known as Link Intime India Pvt Ltd), RTA of the Company for the Quarter ended 31st December, 2024.

pdf

Wockhardt Ltd.

13 Jan 2025

1294.00

-1.23%

Wockhardt Sees New Drugs To Fight Superbugs As Next Growth Driver

NDTV Profit

Wockhardt, founded in 1967, now has six novel formulations in the pipeline, with a second drug Zaynich also expected to launch later in 2025 to tackle complex hospital infections.

Wockhardt Ltd. is trading above its 200 day SMA of 1219.7

Wockhardt's Zaynich antibiotic achieves 97% efficacy against carbapenem-resistant bacteria

Business Line | 13 Jan 2025 2 more

Wockhardt Ltd.

13 Jan 2025

1294.00

-1.23%

Company Update

WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find attached Press Release titled "Zaynich(Zidebactum/Cefepime. WCK 5222)achieves over 97% Efficacy in Clinical Study for serious infections caused by by Meropenem-Resistant Gram-Negative Pathogens."

pdf

Is Wockhardt Ltd. worth buying?

443 Votes:

Buy 73.14%

Sell 17.38%

Hold 9.48%